The Food and Drug Administration is holding a two-day meeting beginning Thursday with an outside advisory committee to evaluate recommendations on whether compounding pharmacies should manufacture seven injectable peptides that have gained popularity in the wellness industry.
The peptides under review include TB-500, BPC-157, and MOTs-C, substances promoted for injury recovery, muscle growth, fat loss, skin health, and metabolic benefits. None have completed the large-scale clinical trials typically required for FDA drug approvals. The FDA’s own career scientists have recommended against authorizing compounding pharmacies to produce any of the seven compounds, noting that available evidence comes primarily from animal studies with limited human data. For TB-500, no human clinical studies were identified in the FDA’s review.
Industry advocates argue that current restrictions on compounding these substances have created an unregulated market of overseas suppliers, incentivizing Americans to self-administer unvetted products. Supporters contend that demand for peptides exists regardless of regulatory status, and that allowing regulated domestic production would be safer than the current alternatives. The American Academy of Peptide Medicine, a professional organization formed earlier this year, has been actively promoting regulatory changes ahead of the advisory committee meeting.
The proceedings reflect a broader tension between Health Secretary Robert F. Kennedy Jr.’s stated agenda to expand access to peptide therapies and concerns from the scientific community. The FDA recently modified the advisory committee’s composition, adding members with ties to the peptide industry and academic experts designated for specific compound expertise. Critics express concern about potential conflicts of interest and the precedent of FDA leadership potentially overriding recommendations from internal scientists. Researchers have also raised questions about whether these peptides, particularly at incorrect doses, could pose risks including unintended cancer promotion or immune system complications.
If the FDA reclassifies any of the peptides, prescribing physicians would gain discretion to recommend them for conditions beyond the narrow indications reviewed by the committee, potentially expanding use cases significantly in clinical practice.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI